We are live on
!
Find out more
ROTUOC
Regents of the University of California Portfolio holdings
AUM
$4.36B
1-Year Est. Return
33.89%
This Fund
S&P 500
This Quarter
Est. Return
+273.42%
1 Year Est. Return
+33.89%
3 Year Est. Return
+86.09%
5 Year Est. Return
+63.96%
10 Year Est. Return
+870.04%
AUM
$190M
AUM Growth
+$137M
(+263%)
Cap. Flow
+$54.9M
Cap. Flow
% of AUM
28.94%
Top 10 Holdings %
Top 10 Hldgs %
91.14%
Holding
31
New
5
Increased
1
Reduced
5
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Allogene Therapeutics
ALLO
|
+$64.7M |
| 2 |
CrowdStrike
CRWD
|
+$3.04M |
| 3 |
XYZ
Block Inc
XYZ
|
+$1.76M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$1.75M |
| 5 |
Uber
UBER
|
+$1.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$15.9M |
| 2 |
Upwork
UPWK
|
+$921K |
| 3 |
MongoDB
MDB
|
+$503K |
| 4 |
Arvinas
ARVN
|
+$449K |
| 5 |
VSM
Versum Materials, Inc.
VSM
|
+$270K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.86% |
| 2 | Technology | 6.45% |
| 3 | Consumer Staples | 4.16% |
| 4 | Financials | 2.71% |
| 5 | Communication Services | 1.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CNST
1
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $82.3M | 43.41% |
1,747,406
-550,000
| -24% | -$15.9M |
|
|
2
Allogene Therapeutics
ALLO
$714M
| $61.1M | 32.21% |
+2,350,930
| New | +$64.7M |
|
3
Estee Lauder
EL
$31.7B
| $6.9M | 3.64% |
33,400
| – | – |
|
4
Guardant Health
GH
$22.2B
| $6.06M | 3.19% |
77,496
-1,910
| -2% | -$138K |
|
|
XYZ
5
Block Inc
XYZ
$47B
| $5.07M | 2.67% |
81,013
+27,498
| +51% | +$1.76M |
|
|
6
CrowdStrike
CRWD
$226B
| $2.89M | 1.52% |
+231,700
| New | +$3.04M |
|
7
Air Products & Chemicals
APD
$67.7B
| $2.4M | 1.26% |
10,200
| – | – |
|
8
ExxonMobil
XOM
$657B
| $2.35M | 1.24% |
33,600
| – | – |
|
9
Merck
MRK
$328B
| $1.97M | 1.04% |
22,637
| – | – |
|
|
10
Berkshire Hathaway Class B
BRK.B
$1.09T
| $1.82M | 0.96% |
+8,043
| New | +$1.75M |
|
|
11
Uber
UBER
$154B
| $1.67M | 0.88% |
+56,052
| New | +$1.66M |
|
12
S&P Global
SPGI
$121B
| $1.64M | 0.86% |
6,000
| – | – |
|
13
Intellia Therapeutics
NTLA
$1.69B
| $1.64M | 0.86% |
111,440
| – | – |
|
|
14
MongoDB
MDB
$35.2B
| $1.51M | 0.8% |
11,492
-3,831
| -25% | -$503K |
|
|
GBT
15
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $1.11M | 0.58% |
13,928
| – | – |
|
16
Verizon
VZ
$195B
| $1.09M | 0.57% |
17,735
| – | – |
|
17
Pfizer
PFE
$150B
| $1.08M | 0.57% |
29,138
| – | – |
|
18
Coca-Cola
KO
$373B
| $996K | 0.53% |
18,000
| – | – |
|
19
Wells Fargo
WFC
$269B
| $974K | 0.51% |
18,106
| – | – |
|
20
Walt Disney
DIS
$178B
| $868K | 0.46% |
6,000
| – | – |
|
21
AT&T
T
$166B
| $848K | 0.45% |
28,715
| – | – |
|
22
Texas Instruments
TXN
$253B
| $834K | 0.44% |
6,500
| – | – |
|
23
Honeywell
HON
$74.6B
| $747K | 0.39% |
4,481
| – | – |
|
|
MRSH
24
Marsh
MRSH
$90.1B
| $579K | 0.31% |
5,200
| – | – |
|
25
GE Aerospace
GE
$379B
| $447K | 0.24% |
8,041
| – | – |
|
Similar funds
SFM
EC
EQF
NEI
FIS
CAU
IUHSA
CW
Regents of the University of California's Q4 2019 Portfolio in Review
As of Q4 2019, Regents of the University of California held 31 positions worth $190M, up 263% from $52.2M the previous quarter. Its ten largest holdings account for 91% of the portfolio.
Regents of the University of California deployed $54.9M of net new capital in Q4 2019, opening 5 new positions and adding to 1 existing holding. Its largest new stake was Allogene Therapeutics: 2,350,930 shares worth $61.1M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 49% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the largest reduction was Constellation Pharmaceuticals, Inc., an estimated $15.9M trimmed.
- Regents of the University of California's largest Q4 2019 buy was Allogene Therapeutics: 2,350,930 shares worth $61.1M.
- Regents of the University of California added most to Block Inc in Q4 2019, an estimated $1.76M increase.
- Regents of the University of California's biggest Q4 2019 reduction was Constellation Pharmaceuticals, Inc., cutting an estimated $15.9M.
- Regents of the University of California fully exited Arvinas in Q4 2019, selling an estimated $449K.
- Regents of the University of California's ten largest holdings make up 91% of its $190M portfolio in Q4 2019.
- Regents of the University of California opened 5 new positions and closed 2 in Q4 2019.
- Regents of the University of California's portfolio value rose 263% quarter-over-quarter to $190M.
Based on Regents of the University of California's 13F filing for Q4 2019, filed 10 Feb 2020.